HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
January 14, 2025
Host Carmel Fisher interviews CEO Chris Bunka on Lexaria’s advancement in creating a superior absorption system for fat soluble nutrients.